Cytokinetics (CYTK) Short Interest Ratio & Short Volume

Short interest is the volume of Cytokinetics shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 15,690,000 shares of CYTK short. 13.75% of Cytokinetics' shares are currently sold short. Learn More on Cytokinetics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CYTK shares currently have a short interest ratio of 13.0. Learn More on Cytokinetics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cytokinetics: Barclays PLC, Jane Street Group LLC, Wolverine Trading LLC, Point72 Asset Management L.P., Parallax Volatility Advisers L.P., Centiva Capital LP, Walleye Capital LLC, PEAK6 Investments LLC, Citigroup Inc., Wolverine Asset Management LLC, and Belvedere Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.75% of Cytokinetics' floating shares are currently sold short.

Cytokinetics saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 15,690,000 shares, an increase of 1.0% from the previous total of 15,540,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Cytokinetics currently has issued a total of 118,014,000 shares. Some of Cytokinetics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cytokinetics currently has a public float of 114,090,000 shares.

13.75% of Cytokinetics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cytokinetics: ORIC Pharmaceuticals, Inc. (16.51%), Phathom Pharmaceuticals, Inc. (25.52%), Nkarta, Inc. (13.56%), Karyopharm Therapeutics Inc. (14.12%), BioXcel Therapeutics, Inc. (0.81%), Teva Pharmaceutical Industries Limited (1.60%), BeiGene, Ltd. (1.12%), Viatris Inc. (2.09%), Summit Therapeutics Inc. (2.31%), Moderna, Inc. (10.02%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling CYTK is an investing strategy that aims to generate trading profit from Cytokinetics as its price is falling. CYTK shares are trading down $1.23 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Cytokinetics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CYTK, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CYTK, twice per month. The most recent reporting period available is October, 31 2024.